While US SCS revenues were almost back to pre-COVID levels in Q320, rising COVID case rates put the brakes on procedure growth by the end of Q420 and the US and WW SCS markets ended down -15%+ in FY20 compared to FY19.
Although spinal cord stimulation (SCS) revenues were almost back to pre-COVID levels in Q320, by the end of Q420, rising COVID case rates in certain geographies put the brakes on procedure growth, resulting in a low-single-digit (LSD) decrease in YoY revenues in both the US and WW in Q420. For the full year (FY), US SCS were down -15.1%, with revenues, according to SmartTRAK SCS Financial Dashboard, totaling ...
Among the many topics covered in the comprehensive Q420/FY20 Spinal Cord Stimulation Market Recap * are: